Unknown

Dataset Information

0

Impact of Bone Marrow miR-21 Expression on Acute Myeloid Leukemia T Lymphocyte Fragility and Dysfunction.


ABSTRACT: BACKGROUND:Acute myeloid leukemia (AML) is a hematopoietic malignancy in which antitumor immunity is impaired. The therapeutic management of AML requires understanding the mechanisms involved in the fragility and immune dysfunction of AML T lymphocytes. METHODS:In this study, T lymphocytes from healthy donors (HD) and AML patients were used. Extracellular vesicles (EVs) from leukemic cells were screened for their microRNA content and impact on T lymphocytes. Flow cytometry, transcriptomic as well as lentiviral transduction techniques were used to carry out the research. RESULTS:We observed increased cell death of T lymphocytes from AML patients. EVs from leukemia myeloid cell lines harbored several miRNAs, including miR-21, and were able to induce T lymphocyte death. Compared to that in HD, miR-21 was overexpressed in both the bone marrow fluid and infiltrating T lymphocytes of AML patients. MiR-21 induces T lymphocyte cell death by upregulating proapoptotic gene expression. It also increases the immunosuppressive profile of T lymphocytes by upregulating the IL13, IL4, IL10, and FoxP3 genes. CONCLUSIONS:Our results demonstrate that miR-21 plays a significant role in AML T lymphocyte dysfunction and apoptosis. Targeting miR-21 may be a novel approach to restore the efficacy of the immune response against AML.

SUBMITTER: Moussa Agha D 

PROVIDER: S-EPMC7563595 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of Bone Marrow miR-21 Expression on Acute Myeloid Leukemia T Lymphocyte Fragility and Dysfunction.

Moussa Agha Douâa D   Rouas Redouane R   Najar Mehdi M   Bouhtit Fatima F   Fayyad-Kazan Hussein H   Lagneaux Laurence L   Bron Dominique D   Meuleman Nathalie N   Lewalle Philippe P   Merimi Makram M  

Cells 20200908 9


<h4>Background</h4>Acute myeloid leukemia (AML) is a hematopoietic malignancy in which antitumor immunity is impaired. The therapeutic management of AML requires understanding the mechanisms involved in the fragility and immune dysfunction of AML T lymphocytes.<h4>Methods</h4>In this study, T lymphocytes from healthy donors (HD) and AML patients were used. Extracellular vesicles (EVs) from leukemic cells were screened for their microRNA content and impact on T lymphocytes. Flow cytometry, transc  ...[more]

Similar Datasets

2024-06-02 | PXD042672 | JPOST Repository
| S-EPMC7583041 | biostudies-literature
| S-EPMC8639599 | biostudies-literature
| S-EPMC8272391 | biostudies-literature
| S-EPMC3684350 | biostudies-literature
| S-EPMC11304419 | biostudies-literature
| S-EPMC5513766 | biostudies-literature
| S-EPMC3259714 | biostudies-literature
| S-EPMC9615331 | biostudies-literature
| S-EPMC6988405 | biostudies-literature